Sarah Jeane Skuli , MD, PhD

BA: University of Pennsylvania Philadelphia, PA, 2011 (Biology, Psychology)

PhD: University of Toulouse Toulouse, France, 2013 (Cancer Biology)

MD: Johns Hopkins University School of Medicine Baltimore, MD, 2017

American Board of Internal Medicine (Hematology) (Certification Date: 11-09-2023 )

American Board of Internal Medicine (Certification Date: 08-16-2021 )

Hematology

Hematology and Oncology

Leukemia

Malignant Melanoma

Acute Lymphocytic Leukemia

Acute Myeloid Leukemia

Bone Marrow Cancers

Myeloma

Hematology

Internal Medicine

Peer Reviewed Publications

Zhang P.; Whipp E.C.; Skuli S.J.; Gharghabi M.; Saygin C.; Sher S.A.; Carroll M.; Pan X.; Eisenmann E.D.; Lai T.H.; Harrington B.K.; Chan W.K.; Youssef Y.; Chen B.; Penson A.; Lewis A.M.; Castro C.R.; Fox N.; Cihan A.; Le Luduec J.B.; DeWolf S.; Kauffman T.; Mims A.S.; Canfield D.; Phillips H.; Williams K.E.; Shaffer J.; Lozanski A.; Doong T.J.; Lozanski G.; Mao C.; Walker C.J.; Blachly J.S.; Daniyan A.F.; Alinari L.; Baiocchi R.A.; Yang Y.; Grieselhuber N.R.; Campbell M.J.; Baker S.D.; Blaser B.W.; Abdel-Wahab O.; Lapalombella R. (05-15-2025. ) TP53 mutations and TET2 deficiency cooperate to drive leukemogenesis and establish an immunosuppress.Journal of Clinical Investigation, , 135 (10 ) , More Information

Skuli S.J.; Bakayoko A.; Kruidenier M.; Manning B.; Pammer P.; Salimov A.; Riley O.; Brake-Sillá G.; Dopkin D.; Bowman M.; Martinez-Gutierrez L.N.; Anderson C.C.; Reisz J.A.; Buono R.; Paul M.; Saland E.; Liccardo F.; DeVine A.; Wong S.; Xu J.P.; Nee E.; Hausler R.; Boettcher S.; Sebti S.M.; Lai C.; Maxwell K.N.; Sarry J.E.; Fruman D.A.; D’Alessandro A.; Mesaros C.; Keith B.; Simon M.C.; Sung P.J.; Wertheim G.; Skuli N.; Bowman R.L.; Matthews A.; Carroll M. (09-01-2025. ) Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgera.Leukemia, , 39 (9 ) ,2087-2098 More Information

Senagolage M.D.; Blaylock H.Z.; Khan S.; Skuli S.J.; Carroll M.P.; McNerney M.E. (08-01-2025. ) NAMPT haploinsufficiency is a collateral lethal therapeutic vulnerability in high-risk myeloid malig.Blood Neoplasia, , 2 (3 ) , More Information

Pottier A.; Park S.; Lee Y.; Liccardo F.; Yang H.; Park J.; Lorant A.; Schnekenburger M.; Brusa D.; Li V.; Valente S.; Mai A.; Skuli S.J.; Carroll M.; Boettcher S.; Sarry J.E.; Cerella C.; Morceau F.; Diederich M. (11-28-2025. ) TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.Cancer Letters, , 633 , More Information

Mahdavi L.; Alikarami F.; Goodrow H.; Lenard A.; Riedel S.S.; Libbrecht C.; Bowser I.; Tasian S.K.; Falkenstein C.D.; Manning B.; Skuli S.; Carroll M.P.; Wertheim G.; Cai S.F.; McGeehan G.; Yu S.; Shi J.; Xie H.M.; Bernt K.M. (01-01-2026. ) Upfront menin-inhibitor resistance in multiply pretreated leukemias.Experimental Hematology, , 153 , More Information

Skuli S.J.; Sheng J.Y.; Bantug E.T.; Zafman N.; Riley C.; Ruck J.M.; Smith K.C.; Snyder C.F.; Smith K.L.; Stearns V.; Wolff A.C. (02-15-2019. ) Survivorship care visits in a high-risk population of breast cancer survivors.Breast Cancer Research and Treatment, , 173 (3 ) ,701-708 More Information

Bosc C.; Broin N.; Fanjul M.; Saland E.; Farge T.; Courdy C.; Batut A.; Masoud R.; Larrue C.; Skuli S.; Espagnolle N.; Pagès J.C.; Carrier A.; Bost F.; Bertrand-Michel J.; Tamburini J.; Récher C.; Bertoli S.; Mansat-De Mas V.; Manenti S.; Sarry J.E.; Joffre C. (12-01-2020. ) Autophagy regulates fatty acid availability for oxidative phosphorylation through mitochondria-endop.Nature Communications, , 11 (1 ) , More Information

Freyer C.W.; Bange E.M.; Skuli S.; Hsu M.; Lin J.; Cuker A.; Cohen A.D.; Garfall A. (11-01-2021. ) Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome in a Patient With Heterozygous CFHR3/CFHR1 De.Clinical Lymphoma Myeloma and Leukemia, , 21 (11 ) ,e845-e849 More Information

Sheng J.Y.; Skuli S.J.; Thorner E.D.; Zafman N.; Riley C.D.; Ruck J.M.; Smith K.C.; Snyder C.; Smith K.L.; Stearns V.; Wolff A.C. (02-01-2022. ) Late effects in a high-risk population of breast cancer survivors.Supportive Care in Cancer, , 30 (2 ) ,1749-1757 More Information

Skuli S.J.; Alomari S.; Gaitsch H.; Bakayoko A.; Skuli N.; Tyler B.M. (05-01-2022. ) Metformin and Cancer, an Ambiguanidous Relationship.Pharmaceuticals, , 15 (5 ) , More Information

Matthews A.H.; Perl A.E.; Luger S.M.; Gill S.I.; Lai C.; Porter D.L.; Skuli S.; Bruno X.J.; Carroll M.P.; Freyer C.W.; Carulli A.; Babushok D.V.; Frey N.V.; Hexner E.O.; Martin M.E.; McCurdy S.R.; Stadtmauer E.A.; Loren A.W.; Paralkar V.R.; Maillard I.P.; Pratz K.W. (08-01-2023. ) Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylatin.American Journal of Hematology, , 98 (8 ) ,1254-1264 More Information

Matthews A.; Fenu E.; Skuli S.J.; Harris J.C.; Bagg A.; Lai C. (01-01-2024. ) Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high s.Leukemia and Lymphoma, , 65 (7 ) ,1012-1015 More Information

Boët E.; Saland E.; Skuli S.; Griessinger E.; Sarry J.E. (01-01-2024. ) Mitohormesis: The keystone of therapeutic resistance in cancer cells.Comptes Rendus Biologies, , 347 ,59-75 More Information

Skuli S.; Matthews A.; Carroll M.; Lai C. (12-01-2024. ) A line in shifting sand: Can we define and target TP53 mutated MDS?.Seminars in Hematology, , 61 (6 ) ,449-456 More Information